Veritas announces restructuring of subsidiary Cannevert TherapeuticsChristian Fernsby ▼ |
America This restructuring includes both permanent and temporary cutbacks
Veritas Pharma announced that it has undertaken steps to restructure and rebuild Cannevert Therapeutics, a wholly owned subsidiary of Veritas.
The company’s intention is to rehire several researchers on a contract basis.
Dr. Michael Walker and Dr. Andrew Hagel will continue to lead and restructure the CTL team.
Veritas’ aim through this restructuring is to create a more focused and nimble research and development infrastructure that reduces costs, can effectively further the company’s achievements from recent clinical trials conducted in Puerto Rico, and is able to scale effectively to provide testing and analytical services to the rapidly expanding cannabis industry. ■
What to read next